Carella, Angelo Michele

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 1,611

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 778

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T. (2016) · PLOS ONE

Lymphoma Diagnosis and TreatmentHealthcare Operations and Scheduling Optimization

Cited by 108

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48

Time Savings With Rituximab Subcutaneous (SC) Injection Vs Rituximab Intravenous (IV) Infusion: Final Analysis From a Time-and-Motion Study In 8 Countries

De Cock, E., Kritikou, P., Tao, S., Wiesner, C., Waterboer, T., & Carella, A. M. (2013) · Blood

Lymphoma Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 7